COMMUNIQUÉS West-GlobeNewswire

Agios Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
12/02/2026
PYRUKYND ® (mitapivat) worldwide net revenues of $20.0 million in fourth quarter and $54.0 million for full year AQVESME™ (mitapivat) for thalassemia now available in U.S. following FDA approval Company will have pre- [...]
Kane Biotech Restarts Commercial Activities and Strengthens North American Management
12/02/2026
Company enters 2026 with renewed business momentum and key commercial appointments in the U.S. and Canada WINNIPEG, Manitoba, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (“Kane Biotech”, “Kane” or [...]
Zymeworks To Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on March 2, 2026
12/02/2026
VANCOUVER, British Columbia, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc . (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, [...]
Catheter Precision, Inc. Secures up to $36.5 Million in Strategic Institutional Financing to Accelerate Growth
12/02/2026
VTAK has Agreed to Terminate its At-The-Market (“ATM”) Equity Offering Program Company Strengthens Balance Sheet and Aligns Institutional Capital for Long-Term Value Creation FORT MILL, S.C., Feb. 12, 2026 (GLOBE [...]
Tilray Expands UK Pharmaceutical Access Through Strategic Agreement with Smartway Pharmaceuticals
12/02/2026
CC Pharma Agreement Bolsters Tilray’s UK Growth, Strengthening Distribution to Pharmacy and Hospital Channels NEW YORK and LONDON, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Tilray Pharma the pharmaceutical division of Tilray [...]
MicrobiotiX and West Africa Centre for Innovative Research and Care Formalize Landmark Phage Therapy Collaboration in Ghana
12/02/2026
SEOUL, South Korea and KUMASI, Ghana, Feb. 12, 2026 (GLOBE NEWSWIRE) -- The West Africa Centre for Innovative Research and Care (WAFCIRC) welcomed MicrobiotiX in Ghana for a formal signing ceremony, marking a historic [...]
Arvinas Announces Appointment of Randy Teel, Ph.D., as President, Chief Executive Officer, and Director
12/02/2026
– Appointment of an experienced Arvinas executive with a proven ability to drive strategy and innovation positions the company for continued momentum and long-term growth – NEW HAVEN, Conn., Feb. 12, 2026 (GLOBE [...]
EDAP Announces Appointment of David Horn to Board of Directors
12/02/2026
EDAP Announces Appointment of David Horn to Board of Directors AUSTIN, Texas, February 12, 2026 – EDAP TMS S.A. (Nasdaq: EDAP) (“the Company” or “EDAP”), a global leader in therapeutic ultrasound technology, today [...]
Lyell Immunopharma Announces Initiation of Patient Dosing in First-of-Its-Kind Phase 3 Head-To-Head CAR T-Cell Clinical Trial in Aggressive Large B-Cell Lymphoma
12/02/2026
PiNACLE – H2H will evaluate the efficacy and safety of rondecabtagene autoleucel (ronde-cel) versus Investigator’s choice of approved CD19 CAR T-cell therapies in patients with aggressive large B-cell lymphoma receiving [...]
NMD Pharma results from Phase 2a study of ignaseclant in Charcot-Marie-Tooth disease Types 1 and 2 selected for late-breaking oral presentation at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
12/02/2026
Aarhus, Denmark, 12 February 2026 – NMD Pharma A/S, a clinical-stage biotechnology company dedicated to developing novel therapies to restore skeletal muscle health, today announced that top-line data results from its [...]
Seres Provides Program and Corporate Updates and Prioritizes Emerging Programs in Inflammatory & Immune Diseases
12/02/2026
Seres has finalized the protocol for the Phase 2 study of SER-155 in patients undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT) with the FDA and has advanced key study startup activities and will [...]
INmune Bio Announces FDA Alignment on Integrated Phase 2b/3 Registration Pathway for XPro1595 in Early Alzheimer’s Disease
12/02/2026
Agency Feedback Provides Regulatory Clarity on Enrichment Strategy and Confirms CDR-SB as Sole Primary Endpoint for Registrational Development Boca Raton, FL, Feb. 12, 2026 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: [...]
Ligand to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
12/02/2026
JUPITER, Fla., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report fourth quarter and full year 2025 financial results on Thursday, February 26, 2026 [...]
BioXcel Therapeutics Completes Market Opportunity Assessment and Advances Commercialization Plans for IGALMI® in the At-Home Setting
12/02/2026
Third party commercial assessment shows larger than expected potential total addressable market for IGALMI ® in the at-home setting Strong prescriber interest, patient demand, and positive payer feedback on formulary [...]
Orion Group Financial Statement Release January–December 2025
12/02/2026
ORION CORPORATION FINANCIAL STATEMENT RELEASE 1–12/2025 12 FEBRUARY 2026 at 12:00 EET Orion Group Financial Statement Release January–December 2025 October–December 2025 Highlights Net sales totalled EUR 695.3 (October– [...]
Velocity Clinical Research Appoints UK Medical Director
12/02/2026
DURHAM, N.C. , Feb. 12, 2026 (GLOBE NEWSWIRE) -- Velocity Clinical Research today announces the appointment of Dr. Ronnie Beboso as UK Medical Director, strengthening the organization’s medical leadership as it [...]
Cronos Group Inc. to Hold 2025 Fourth Quarter and Full-Year Earnings Conference Call on February 26, 2026
12/02/2026
TORONTO, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”) will hold its 2025 fourth quarter and full-year earnings conference call on Thursday, February 26, 2026 [...]
The Board of Directors of Orion Corporation decided on a new plan period for the Long-term Incentive program for the company’s key persons
12/02/2026
ORION CORPORATION STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE 12 FEBRUARY 2026 at 13.12 EET The Board of Directors of Orion Corporation decided on a new plan period for [...]
BridgeBio Reports Positive Phase 3 Topline Results for Oral Infigratinib with the First Statistically Significant Improvements in Body Proportionality in Achondroplasia
12/02/2026
- PROPEL 3 successfully met the primary endpoint of change from baseline in AHV at Week 52 (p<0.0001) - Change from baseline in AHV was superior to placebo at Week 52 with a mean treatment difference against placebo [...]

Pages